Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger’s Disease

Brief Title

Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

Official Title

Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

Brief Summary

      The purpose of this expanded access program (EAP) is to provide Selexipag (Uptravi) for the
      treatment of participant with non-healing wound, buerger's disease.
    



Study Type

Expanded Access




Condition

Non-healing Wound

Intervention

Selexipag


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug







Ages

 - 


Contacts

Actelion Clinical Trial, 844-434-4210, [email protected]



Administrative Informations


NCT ID

NCT04914247

Organization ID

CR108669


Responsible Party

Sponsor

Study Sponsor

Actelion


Study Sponsor

Actelion Clinical Trial, Study Director, Actelion


Verification Date

May 2021